Oxycodone Hydrochloride side effects: what 215,964 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Oxycodone Hydrochloride
Who reports
215,964 reports · 90% serious · 52,889 with death outcome · 45% female
Used for
Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.
What it is
Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,192 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Polysubstance abuse | 400 | 160.7 136.8–188.7ROR 161.0 · calibrated p 3e-9 ✓ | 60.1 EB05 55.3 · IC025 +5.6 3/3 methods agree | Reporting / coding artifact | serious n=399 | no trial arm names this drug |
| Drug dependence | 100,436 | 158.4 157.0–159.9ROR 295.3 · calibrated p 1e-11 ✓ | 59.9 EB05 59.6 · IC025 +5.9 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 49.6 · serious PRR 38.9 · 94% consumer | no trial arm names this drug |
| Learning disability | 3,067 | 128.8 122.0–135.9ROR 130.6 · calibrated p 1e-8 ✓ | 55.2 EB05 53.5 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=3,059 · 100% consumer | no trial arm names this drug |
| Neonatal hypoacusis | 126 | 112.7 87.0–145.9ROR 112.8 · calibrated p 7e-8 ✓ | 51.7 EB05 44.5 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=126 · 100% consumer | no trial arm names this drug |
| Vision abnormal neonatal | 222 | 107.4 88.6–130.1ROR 107.5 · calibrated p 8e-8 ✓ | 50.7 EB05 45.3 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=222 · 100% consumer | no trial arm names this drug |
| Presbyacusis | 143 | 82.7 66.1–103.4ROR 82.7 · calibrated p 6e-7 ✓ | 44.4 EB05 38.6 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=143 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Drug withdrawal syndrome | 36,964 | 69.3 68.4–70.2ROR 83.4 · calibrated p 4e-7 ✓ | 40.5 EB05 40.1 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 12.7 · serious PRR 31.9 · 83% consumer | no trial arm names this drug |
| Emotional distress | 48,597 | 64.6 63.9–65.3ROR 83.1 · calibrated p 4e-7 ✓ | 38.8 EB05 38.5 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.0 · serious PRR 27.3 · 93% consumer | no trial arm names this drug |
| Drug abuser | 2,262 | 55.2 52.4–58.1ROR 55.8 · calibrated p 7e-6 ✓ | 35.2 EB05 34.0 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=2,261 | no trial arm names this drug |
| Self esteem decreased | 806 | 47.7 43.8–51.9ROR 47.9 · calibrated p 2e-5 ✓ | 32.0 EB05 30.2 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=805 · 100% consumer | no trial arm names this drug |
| Drug diversion | 1,887 | 47.5 45.0–50.2ROR 47.9 · calibrated p 2e-5 ✓ | 32.0 EB05 30.8 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=905 · 96% consumer | no trial arm names this drug |
| Drug withdrawal syndrome neonatal | 4,709 | 44.4 42.9–46.0ROR 45.4 · calibrated p 2e-5 ✓ | 30.6 EB05 29.8 · IC025 +4.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 19.5 · 100% consumer | no trial arm names this drug |
| Multiple drug overdose accidental | 143 | 43.0 35.3–52.4ROR 43.1 · calibrated p 4e-5 ✓ | 29.8 EB05 25.9 · IC025 +4.5 3/3 methods agree | Labeled (related wording) related wording | serious n=143 · ♀ 0% (drug 45%) · 100% clinician | no trial arm names this drug |
| Substance dependence | 201 | 41.4 35.1–48.9ROR 41.5 · calibrated p 5e-5 ✓ | 29.1 EB05 25.8 · IC025 +4.5 3/3 methods agree | Labeled (related wording) related wording | serious n=201 · 100% consumer | no trial arm names this drug |
| Developmental delay | 2,714 | 41.1 39.3–42.9ROR 41.6 · calibrated p 4e-5 ✓ | 29.0 EB05 28.0 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 18.6 · 100% consumer | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 157 | 39.1 32.4–47.0ROR 39.1 · calibrated p 7e-5 ✓ | 27.9 EB05 24.4 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=157 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Victim of homicide | 160 | 38.1 31.7–45.8ROR 38.1 · calibrated p 8e-5 ✓ | 27.4 EB05 24.0 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=160 · 100% consumer | no trial arm names this drug |
| Drug tolerance increased | 209 | 35.0 29.9–41.0ROR 35.0 · calibrated p 1e-4 ✓ | 25.8 EB05 23.0 · IC025 +4.4 3/3 methods agree | Labeled (related wording) related wording | serious n=201 · 78% consumer | no trial arm names this drug |
| Imprisonment | 443 | 31.7 28.4–35.3ROR 31.7 · calibrated p 2e-4 ✓ | 24.0 EB05 22.2 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=443 · ♀ 21% (drug 45%) · 100% consumer | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 152 | 28.4 23.7–34.1ROR 28.4 · calibrated p 4e-4 ✓ | 22.0 EB05 19.3 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious n=152 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Overdose | 49,032 | 28.2 28.0–28.5ROR 36.2 · calibrated p 9e-5 ✓ | 22.0 EB05 21.8 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 8.7 · serious PRR 17.6 · 89% consumer | no trial arm names this drug |
| Deep vein thrombosis postoperative | 436 | 27.6 24.8–30.7ROR 27.6 · calibrated p 4e-4 ✓ | 21.6 EB05 19.9 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=436 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Delusional disorder, unspecified type | 163 | 26.9 22.6–32.0ROR 26.9 · calibrated p 5e-4 ✓ | 21.1 EB05 18.5 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=163 · 100% clinician | no trial arm names this drug |
| Lupus vulgaris | 257 | 26.5 23.1–30.5ROR 26.6 · calibrated p 5e-4 ✓ | 20.9 EB05 18.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=257 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 428 | 26.0 23.3–28.9ROR 26.0 · calibrated p 6e-4 ✓ | 20.6 EB05 19.0 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=426 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Detoxification | 73 | 25.5 19.7–33.1ROR 25.5 · calibrated p 7e-4 ✓ | 20.2 EB05 16.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=70 · ♀ 0% (drug 45%) · 100% consumer | no trial arm names this drug |
| C-reactive protein | 186 | 24.8 21.1–29.2ROR 24.9 · calibrated p 7e-4 ✓ | 19.9 EB05 17.6 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=186 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Swollen joint count increased | 606 | 23.2 21.3–25.4ROR 23.3 · calibrated p 1e-3 ✓ | 18.8 EB05 17.6 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | serious n=606 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| X-ray abnormal | 338 | 22.5 20.0–25.3ROR 22.5 · calibrated p 0.001 ✓ | 18.4 EB05 16.8 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious n=338 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 1,373 | 22.2 20.9–23.5ROR 22.3 · calibrated p 0.001 ✓ | 18.1 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 11.5 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Muscle injury | 1,531 | 22.1 20.9–23.4ROR 22.2 · calibrated p 0.001 ✓ | 18.1 EB05 17.4 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious PRR 12.5 · ♀ 100% (drug 45%) · 91% clinician | no trial arm names this drug |
| Drug tolerance | 936 | 21.8 20.3–23.4ROR 21.9 · calibrated p 0.001 ✓ | 17.9 EB05 16.9 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=881 · 71% consumer | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 1,165 | 21.3 20.0–22.7ROR 21.4 · calibrated p 0.001 ✓ | 17.6 EB05 16.7 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=1,162 · ♀ 100% (drug 45%) · 92% clinician | no trial arm names this drug |
| Facet joint syndrome | 566 | 21.1 19.2–23.1ROR 21.1 · calibrated p 0.002 ✓ | 17.4 EB05 16.2 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=566 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 1,271 | 21.0 19.7–22.3ROR 21.1 · calibrated p 0.002 ✓ | 17.4 EB05 16.6 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | serious PRR 11.1 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Pleural fibrosis | 180 | 20.4 17.4–23.9ROR 20.4 · calibrated p 0.002 ✓ | 16.9 EB05 14.9 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=180 · ♀ 100% (drug 45%) | no trial arm names this drug |
| Rheumatic fever | 760 | 20.3 18.8–21.9ROR 20.4 · calibrated p 0.002 ✓ | 16.9 EB05 15.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=760 · ♀ 100% (drug 45%) · 94% clinician | no trial arm names this drug |
| Substance abuse | 1,412 | 20.2 19.0–21.4ROR 20.3 · calibrated p 0.002 ✓ | 16.8 EB05 16.1 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | serious PRR 11.8 · 80% consumer | no trial arm names this drug |
| Dislocation of vertebra | 385 | 20.2 18.1–22.5ROR 20.2 · calibrated p 0.002 ✓ | 16.8 EB05 15.4 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=385 · ♀ 100% (drug 45%) · 92% clinician | no trial arm names this drug |
| Pleural thickening | 117 | 20.0 16.3–24.4ROR 20.0 · calibrated p 0.002 ✓ | 16.6 EB05 14.2 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=117 · ♀ 100% (drug 45%) · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 105,019 | 53.353.0–53.6 | signal |
| Depression | 8,541 | 3.02.9–3.1 | signal |
| Suicidality | 5,887 | 2.42.3–2.4 | signal |
| Interstitial lung disease | 1,483 | 1.51.4–1.6 | raised |
| Liver injury | 4,037 | 1.31.3–1.3 | raised |
| Serious infection | 8,059 | 1.01.0–1.0 | no difference |
| Osteonecrosis | 599 | 1.00.9–1.1 | no difference |
| Fall / fracture | 3,665 | 0.90.9–1.0 | lower than other drugs |
| Venous thromboembolism | 1,954 | 0.90.8–0.9 | lower than other drugs |
| Rhabdomyolysis / myopathy | 703 | 0.80.8–0.9 | lower than other drugs |
| Kidney injury | 3,875 | 0.80.8–0.8 | lower than other drugs |
| Hyponatraemia | 658 | 0.80.7–0.9 | lower than other drugs |
| Thrombocytopenia | 1,781 | 0.80.7–0.8 | lower than other drugs |
| Anaemia | 2,311 | 0.70.7–0.8 | lower than other drugs |
| Seizure | 1,455 | 0.70.7–0.8 | lower than other drugs |
| Myocardial infarction | 1,481 | 0.70.7–0.7 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug dependence | 100,436 | 158.4 157.0–159.9ROR 295.3 · calibrated p 1e-11 ✓ | 59.9 EB05 59.6 · IC025 +5.9 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 49.6 · serious PRR 38.9 · 94% consumer | no trial arm names this drug |
| Pain | 56,251 | 9.7 9.6–9.8ROR 12.7 · calibrated p 0.013 ✓ | 8.9 EB05 8.8 · IC025 +3.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 3.0 · serious PRR 8.6 | no trial arm names this drug |
| Overdose | 49,032 | 28.2 28.0–28.5ROR 36.2 · calibrated p 9e-5 ✓ | 22.0 EB05 21.8 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 8.7 · serious PRR 17.6 · 89% consumer | no trial arm names this drug |
| Emotional distress | 48,597 | 64.6 63.9–65.3ROR 83.1 · calibrated p 4e-7 ✓ | 38.8 EB05 38.5 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 4.0 · serious PRR 27.3 · 93% consumer | no trial arm names this drug |
| Drug withdrawal syndrome | 36,964 | 69.3 68.4–70.2ROR 83.4 · calibrated p 4e-7 ✓ | 40.5 EB05 40.1 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 12.7 · serious PRR 31.9 · 83% consumer | no trial arm names this drug |
| Death | 23,830 | 2.7 2.7–2.8ROR 3.0 · calibrated p 0.643 | 2.7 EB05 2.7 · IC025 +1.4 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 1.5 · serious PRR 1.7 · 75% consumer | no trial arm names this drug |
| Toxicity to various agents | 14,030 | 8.8 8.6–8.9ROR 9.3 · calibrated p 0.041 ✓ | 8.1 EB05 8.0 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.2 · serious PRR 5.3 | no trial arm names this drug |
| Drug abuse | 8,073 | 10.3 10.0–10.5ROR 10.6 · calibrated p 0.026 ✓ | 9.4 EB05 9.2 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 7.8 · serious PRR 6.0 · 75% consumer | no trial arm names this drug |
| Anxiety | 8,029 | 2.8 2.7–2.8ROR 2.9 · calibrated p 0.676 | 2.7 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 2.3 | no trial arm names this drug |
| Depression | 7,922 | 3.5 3.4–3.5ROR 3.5 · calibrated p 0.474 | 3.4 EB05 3.3 · IC025 +1.7 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.3 · serious PRR 2.9 | no trial arm names this drug |
| Nausea | 7,817 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.281 | 1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 0.9 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 6,967 | 0.5 0.5–0.5ROR 0.5 · calibrated p 0.047 ✓ | 0.5 EB05 0.5 · IC025 -1.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.2 · serious PRR 0.6 | no trial arm names this drug |
| Fatigue (tiredness) | 6,671 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.199 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 0.8 · ♀ 66% (drug 45%) | no trial arm names this drug |
| Vomiting | 5,829 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.451 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 1.0 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 5,180 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.170 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 0.7 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Learning disability — n=3,067, PRR 128.8
- Neonatal hypoacusis — n=126, PRR 112.7
- Vision abnormal neonatal — n=222, PRR 107.4
- Presbyacusis — n=143, PRR 82.7
- Emotional distress — n=48,597, PRR 64.6
- Drug abuser — n=2,262, PRR 55.2
- Self esteem decreased — n=806, PRR 47.7
- Developmental delay — n=2,714, PRR 41.1
- Victim of homicide — n=160, PRR 38.1
- Imprisonment — n=443, PRR 31.7
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Oxycodone Hydrochloride?
In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone Hydrochloride are pain, emotional distress, drug withdrawal syndrome, toxicity to various agents, anxiety, depression. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Oxycodone Hydrochloride have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Do FAERS signals prove that Oxycodone Hydrochloride causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6b6db42b-9821-4aa6-8566-297037d84079, effective 20260723; matched on
openfda.generic_name.exact:"OXYCODONE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5284603 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,232 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
OXYCODONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.